CEO William Sibold stated, "we ended our first full year on the market at nearly $1 billion in net sales and solidified Rezdiffra as the foundational therapy in MASH." Sibold highlighted that the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results